Lexology December 1, 2022
Ropes & Gray LLP

Click here to listen to the audio

In this Ropes & Gray podcast, health care partners Margaux Hall and Stephanie Webster and counsel David Ault explore drug pricing reforms and limits on agency action. In the months leading up to the midterm elections, we saw a flurry of activity around drug pricing, and now, in the wake of midterms, we see heightened bipartisan interest in the topic. Listen in to hear about some of the key recent events and a discussion on the fundamental question of how far agencies can go in regulating drug pricing.

Transcript:

Margaux Hall: Hello, everyone, and welcome to this podcast. Today, we will be discussing drug pricing reforms and limits on agency action. In the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech, Trends
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs
Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
Regeneron expands in gene editing with Mammoth deal

Share This Article